ASCO15: Saladax Biomedical Inc. (SBI) Announces Presentation Of CEPAC-TDM Study Of Paclitaxel In Non-Small Cell Lung Cancer At 2015 ASCO Meeting

BETHLEHEM, Pa.--(BUSINESS WIRE)--Saladax Biomedical, Inc. recently presented results from the largest, randomized, prospective dose adjustment-therapeutic drug monitoring (TDM) trial ever conducted in oncology: evaluating 304 patients over six years (abstract # 8051). The CEPAC-TDM phase III study in advanced Non-Small Cell Lung Cancer (NSCLC) patients (ClinicalTrials.gov Identifier NCT01326767) compared two arms – one with dose optimization [pharmacokinetically (PK)-guided] to one with standard dosing.

Help employers find you! Check out all the jobs and post your resume.